GLP-1s for insulin resistance: what the science actually supports

What's this video probably claiming?

Based on the caption and hashtags, @apriljxo is likely telling a personal story about using a GLP-1 receptor agonist, probably semaglutide or tirzepatide, to manage insulin resistance and prediabetes rather than for weight loss as a primary goal. As a self-described body positive influencer, she's probably framing this as a metabolic health decision rather than a cosmetic one, which is actually a more clinically defensible position than most GLP-1 content on TikTok. She may be discussing symptoms she experienced, how she got diagnosed with insulin resistance or prediabetes, and why her doctor prescribed a GLP-1. She might also be pushing back against the assumption that GLP-1s are purely "diet drugs," which, to be fair, is a reasonable point worth making. The body positivity angle likely means she's addressing the stigma around taking these medications while not explicitly pursuing weight loss as the stated goal.

What does the science actually show?

GLP-1 receptor agonists have legitimate, well-documented effects on insulin secretion and glucose metabolism that go well beyond weight loss. The SUSTAIN and PIONEER trial series for semaglutide showed meaningful reductions in HbA1c, typically 1.0 to 1.8 percentage points, in people with type 2 diabetes. For prediabetes specifically, the STEP 1 trial (Wilding et al., 2021, NEJM) found that weekly 2.4mg semaglutide reduced progression to type 2 diabetes as a secondary outcome. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed it reduced fasting insulin levels significantly alongside weight changes. The mechanism is real: GLP-1 agonists stimulate glucose-dependent insulin secretion from pancreatic beta cells, reduce glucagon release, and slow gastric emptying. That said, most of these trials enrolled people who were also losing weight, which makes it genuinely hard to separate metabolic improvements from weight-loss-driven improvements. The independent metabolic benefit in weight-stable patients is less clearly established in long-term data.

Where does the social media noise diverge from clinical reality?

The biggest problem in GLP-1 content generally is the flattening of a complex diagnosis. "Insulin resistance" as a social media concept has become almost meaninglessly broad. Clinically, insulin resistance is measured through fasting insulin, HOMA-IR scores, or oral glucose tolerance tests, and the thresholds for when to treat with a GLP-1 versus lifestyle modification alone are genuinely debated among endocrinologists. A lot of creators, and potentially this one, may be using insulin resistance as a catch-all term without specifying their actual diagnostic picture. There's also a tendency in this content niche to imply that GLP-1s are the only or best tool for prediabetes, when the Diabetes Prevention Program (Knowler et al., 2002, NEJM) found that structured lifestyle intervention reduced progression to diabetes by 58 percent compared to 31 percent for metformin. GLP-1s weren't even in that comparison. None of that means this creator is wrong to be on a GLP-1, but the framing of "GLP-1 to treat insulin resistance" can make it sound like a settled first-line treatment when the evidence hierarchy is more complicated.

What should you actually know?

If you have prediabetes or diagnosed insulin resistance, GLP-1 receptor agonists are a legitimate option, but they're not universally appropriate as a first-line choice. The American Diabetes Association's 2024 Standards of Care recommend lifestyle intervention as the foundation, with pharmacotherapy added based on individual risk factors, comorbidities, and patient preference. Metformin remains the most studied and lowest-cost pharmacological option for prediabetes prevention. GLP-1s like semaglutide are increasingly used for this population, but insurance coverage for prediabetes indications is inconsistent and the long-term data specifically in non-diabetic insulin-resistant adults is thinner than the weight loss or type 2 diabetes literature. The body positivity framing in this video may also lead some viewers to conclude they can take a GLP-1 without any lifestyle changes, which misrepresents how these medications work best. They are adjuncts, not replacements, for diet and movement changes, regardless of your relationship with body image.